WALTHAM, Mass. — Aldevron, a Danaher company and a global leader in the production of DNA, RNA, and proteins for genomic medicine, has announced the launch of a new Innovation Center in Waltham, Massachusetts, deepening its presence in the Greater Boston biotech corridor.
The new facility is expected to accelerate breakthroughs in genomic therapies by expanding Aldevron’s capabilities in cell-free DNA, molecular biology, gene editing, and mRNA analytics. By situating the center in Waltham, the company aims to foster closer collaboration with clients and streamline the development of advanced therapeutics in one of the world’s leading life sciences hubs.
“Establishing a presence in Waltham puts Aldevron at the crossroads of scientific discovery,” said Venkata Indurthi, Chief Scientific Officer at Aldevron. “This Innovation Center is a launchpad for transformative research, empowering us to innovate, collaborate and grow alongside the brightest minds in biotech.”
The Waltham site will complement Aldevron’s existing operations in Fargo, North Dakota, and Madison, Wisconsin, and is expected to serve as a magnet for top talent from the Boston area’s vibrant biotech ecosystem.
Jennifer Meade, President of Aldevron, cited the company’s role in the recent delivery of a CRISPR-based therapy for “Baby KJ” as an example of its ongoing impact in the field.
“Our recent role in the groundbreaking ‘Baby KJ’ CRISPR therapy delivery demonstrates the life-changing impact that comes from investing in innovation,” Meade said. “As one of the most established biotech partners in the U.S., this expansion is a natural evolution—opening new opportunities for growth, deeper client partnerships, and greater support for the scientists shaping the future of medicine.”
